摘要：研究人员找到了一种人类抗体，它能广泛地中和II-组流感病毒-A，其中包括可引起严重病情的H3N2病毒及H7N7禽流感病毒。 Damian Ekiert及其同事说，将来，这种新的抗体也许能够与另外一种已经显示了对I-组流感病毒-A具有广谱疗效的抗体组成一种“鸡尾酒”来开发新型的流感疫苗。 流感病毒株一直处于演化之中，这使得人们很难将一种疫苗与在某特定季节中流行的特别流感进行匹配。 一种针对多种多样病毒株的通用疫苗可帮助解决这一问题。 Ekiert及其同事对II-组抗体（称作CR8020）的晶体结构的分析显示，该抗体的标靶是II-组病毒表面血凝素蛋白的一部份，其作用是干扰该蛋白附着并感染细胞的能力。 研究人员说，这一蛋白区域似乎始终存在于多种II-组流感病毒中，而且该区域与I-组抗体的标靶区域不同。
生物探索推荐英文论文摘要：
Science DOI: 10.1126/science.1204839
A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses
Abstract
Current flu vaccines provide only limited coverage against seasonal strains of influenza viruses. The identification of VH1-69 antibodies that broadly neutralize almost all influenza A group 1 viruses constituted a breakthrough in the influenza field. Here, we report the isolation and characterization of a human monoclonal antibody CR8020 with broad neutralizing activity against most group 2 viruses, including H3N2 and H7N7, which cause severe human infection. The crystal structure of Fab CR8020 with the 1968 pandemic H3 hemagglutinin (HA) reveals a highly conserved epitope in the HA stalk distinct from the epitope recognized by the VH1-69 group 1 antibodies. Thus, a cocktail of two antibodies may be sufficient to neutralize most influenza A subtypes and, hence, enable development of a universal flu vaccine and broad-spectrum antibody therapies.
